On this page
Epidermolysis bullosa simplex
People with EBS have skin that is prone to blistering, often from minor friction or trauma. This condition primarily affects the outermost layer of the skin and can range in severity, impacting daily life for those affected from infancy onwards.
Overview
Epidermolysis Bullosa Simplex (EBS) encompasses several types of inherited skin conditions where the skin is unusually fragile and forms blisters readily. These blisters typically occur in the outermost layer of the skin, known as the epidermis, in response to mild friction, heat, or trauma [PMID:17908866]. EBS is typically present from birth or early infancy and is one of the most common forms of epidermolysis bullosa (EB).
The condition arises from genetic changes that affect the proteins responsible for strengthening skin cells. Although there are different subtypes of EBS, they all share the common feature of blister formation. The severity can vary significantly between individuals, even within the same family, ranging from mild blistering on hands and feet to more widespread and persistent issues.
Symptoms & clinical features
The primary symptom of EBS is the development of skin blisters. These can appear on various parts of the body but are commonly found on areas subjected to friction, such as the hands, feet, elbows, and knees. The blisters are often fluid-filled and can be painful. After healing, they usually do not leave scars, unlike some other forms of EB, though repeat blistering in the same area can lead to skin thickening or pigmentation changes.
Depending on the specific subtype of EBS, other symptoms might include thickening of the skin on the palms and soles (palmoplantar keratoderma), or changes to the fingernails and toenails. In milder forms, blistering may only be noticeable during warm weather or intense physical activity, while more severe forms can lead to chronic blistering and secondary skin infections [PMID:33675094]. Less commonly, blisters can also appear inside the mouth or throat, causing discomfort with eating.
Video: Genetics 101
Affected organs
EBS primarily affects the skin, which is the body's largest organ. The blistering occurs within the epidermis, the outermost layer of the skin. This fragility can impact skin on many parts of the body, particularly areas exposed to friction and pressure. The nails are also frequently affected, becoming thickened or malformed. While the main impact is on the skin, blistering can occasionally extend to mucous membranes, such as those lining the mouth, which can make eating difficult and painful.
Risks & severity
The severity of EBS can range considerably. Some individuals experience mild blistering outbreaks, often confined to the hands and feet, which may improve with age. In these cases, the condition might only cause minor discomfort and does not significantly impact daily life. Other individuals may have more widespread and recurrent blistering, leading to chronic wounds and an increased risk of skin infections.
While EBS is generally considered a less severe form of epidermolysis bullosa, some subtypes can cause significant discomfort and require ongoing care. The lifetime risk of developing skin cancer, such as squamous cell carcinoma, is not significantly increased in most forms of EBS, unlike in some other EB types [PMID:33675094]. EBS is typically present from birth, and the age of onset helps to differentiate it from adult-onset blistering conditions.
Genetic causes
EBS is caused by genetic changes (also known as variants or mutations) in genes that provide instructions for making proteins crucial for the structural integrity of skin cells. One such gene commonly associated with EBS is KRT5.
KRT5 provides instructions for producing keratin 5, a protein that forms intermediate filaments. These filaments are tough, rope-like structures that provide structural support and strength to skin cells, especially in the epidermis. Pathogenic variants in KRT5 can lead to the production of faulty keratin 5 proteins, resulting in weakened skin cells. This weakness makes the skin susceptible to tearing and blistering with minimal trauma or friction, as the cells cannot withstand normal mechanical stress [PMID:17908866].
- KRT5 keratin 5
Inheritance pattern
Epidermolysis Bullosa Simplex can be inherited in an autosomal dominant (AD) or autosomal recessive (AR) pattern. In autosomal dominant inheritance, only one copy of an altered gene is needed to cause the condition. This means if a parent has EBS due to an autosomal dominant gene change, there is a 50% chance with each pregnancy that their child will also inherit the altered gene and develop the condition. Many sporadic cases (new gene changes) are also seen.
In autosomal recessive inheritance, both copies of a gene must have a pathogenic change for an individual to develop the condition. This means the person inherits one altered copy from each parent, who are typically unaffected carriers. If both parents are carriers, there is a 25% chance with each pregnancy that their child will inherit two altered copies and be affected, a 50% chance they will be an unaffected carrier, and a 25% chance they will inherit two unaffected copies. Genetic counselling is available to help families understand these inheritance patterns and their implications.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
The diagnosis of Epidermolysis Bullosa Simplex is suspected based on the characteristic clinical features, especially the presence of fragile skin and recurrent blistering. A definitive diagnosis is typically confirmed through genetic testing. This testing involves analysing a blood or skin sample to identify pathogenic variants in genes known to cause EBS, such as KRT5.
In the UK, if EBS is suspected, a referral to a specialist paediatric dermatologist or clinical geneticist would be appropriate. Genetic testing for EBS is available through the NHS Genomic Medicine Service (GMS) under relevant R-codes, such as R253 Epidermolysis bullosa and other inherited blistering disorders, typically after clinical assessment. A skin biopsy may also be taken, where specialist microscopy can show the level at which the skin separates, helping to differentiate EBS from other types of epidermolysis bullosa.
Management & lifestyle
While there is currently no cure for Epidermolysis Bullosa Simplex, management focuses on preventing blisters, protecting the skin, and treating any complications. This typically involves careful skin care, such as applying protective dressings to vulnerable areas and using emollient creams to keep the skin moisturised and supple. Avoiding activities that cause friction or trauma can also help minimise blistering.
If blisters do occur, they should be lanced (pricked) with a sterile needle to drain the fluid, which can help prevent them from spreading and reduce pain. Specialist nurses often provide guidance on wound care and appropriate dressings. Pain relief, prevention of infection, and nutritional support may also be necessary, especially if oral blistering affects eating. Regular follow-up with a dermatologist is important to monitor the condition and address any new concerns. Management plans are always individualised and developed in consultation with healthcare professionals, following NHS guidelines.
UK care pathway
In the UK, individuals suspected of having Epidermolysis Bullosa Simplex would typically enter the NHS Genomic Medicine Service (GMS) pathway. This often begins with a referral from a GP to a clinical geneticist or a specialist dermatologist. These specialists can assess the clinical features, arrange appropriate diagnostic tests, and provide genetic counselling. Genetic testing for EBS is accessible via the GMS, using specific R-codes such as R253 for inherited blistering disorders, facilitating a precise diagnosis.
Following diagnosis, families will have access to genetic counsellors who can explain the inheritance patterns, implications for family planning, and offer support resources. Multidisciplinary teams, often including dermatologists, specialist nurses, and sometimes pain management specialists or dieticians, work together to provide comprehensive and individualised care managed within NHS frameworks.
Frequently asked questions
Is Epidermolysis Bullosa Simplex curable?
Currently, there is no cure for Epidermolysis Bullosa Simplex. Management focuses on preventing blisters, protecting the skin, and treating any symptoms or complications. Research into potential new treatments is ongoing.
Will my child inherit Epidermolysis Bullosa Simplex if I have it?
It depends on the inheritance pattern of your specific type of EBS. If it's autosomal dominant, there's a 50% chance with each child. If it's autosomal recessive, both parents usually need to be carriers for a child to be affected. Genetic counselling can provide personalised risk assessments.
Are there different types of Epidermolysis Bullosa Simplex?
Yes, there are several subtypes of EBS, which vary in genetic cause, severity, and how symptoms present. Examples include localised EBS (Weber-Cockayne), generalised intermediate EBS (Koebner), and generalised severe EBS (Dowling-Meara). All result in blistering within the epidermis.
Can diet affect Epidermolysis Bullosa Simplex?
While diet doesn't cause or cure EBS, maintaining good nutrition is important, especially if blistering within the mouth or throat makes eating difficult. A balanced diet supports overall health and skin healing. A dietitian may be involved if there are nutritional concerns.
How can I prevent blistering with Epidermolysis Bullosa Simplex?
Preventing blisters involves protecting the skin from friction and trauma. This can include wearing soft, well-fitting clothing and shoes, applying protective dressings to vulnerable areas, and avoiding activities that put stress on the skin. Regular moisturising of the skin is also often recommended.
References
- Adam MP, Bick S, Mirzaa GM. Epidermolysis Bullosa Simplex. 1993. PMID: 20301543
- Khani P, Ghazi F, Zekri A. Keratins and epidermolysis bullosa simplex. Journal of cellular physiology. 2018. PMID: 30078200
- Bchetnia M, Powell J, McCuaig C. Pathological Mechanisms Involved in Epidermolysis Bullosa Simplex: Current Knowledge and Therapeutic Perspectives. International journal of molecular sciences. 2024. PMID: 39273442
- Sprecher E. Epidermolysis bullosa simplex. Dermatologic clinics. 2010. PMID: 19945613
- Fine JD. Malignant melanoma and epidermolysis bullosa simplex. JAMA dermatology. 2013. PMID: 23966137
- Kyrova J, Kopeckova L, Buckova H. Epidermolysis bullosa simplex with muscular dystrophy. Review of the literature and a case report. Journal of dermatological case reports. 2016. PMID: 28400893
- Coulombe PA, Fuchs E. Epidermolysis bullosa simplex. Seminars in dermatology. 1993. PMID: 7692916
- Hanrahan GB, Zhu A, Reusch DB. Treatment Landscape for Epidermolysis Bullosa Simplex: A Review of Established and Emerging Therapies. Pediatric dermatology. 2026. PMID: 41723962